Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company focused on leveraging its cell-free protein synthesis platform, XpressCF, to create a broad variety of complex, next-generation protein therapeutics for oncology. The Company currently has two wholly owned product candidates: STRO-002, an ADC directed against folate receptor-alpha (FolRα) for patients with ovarian and endometrial cancers, and STRO-001, an ADC directed against CD74 for patients with multiple myeloma and non-Hodgkin’s lymphoma (NHL).